Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Positive confirmatory data from atopic dermatitis cohort of EDP-1815 phase Ib trial

Jan. 21, 2021

Arcutis initiates pivotal phase III studies of roflumilast cream in patients with atopic dermatitis

Jan. 14, 2021

Dovobet Foam approved in Japan for psoriasis

Jan. 13, 2021

Cara opens phase II trial of oral difelikefalin for notalgia paresthetica pruritus

Jan. 11, 2021

New phase II trial evaluates SCD-044 for moderate to severe plaque psoriasis

Jan. 5, 2021

New CTP synthase 1 inhibitors described by Step Pharma

Dec. 29, 2020

New acetyl-CoA carboxylase inhibitors discovered at Almirall

Dec. 29, 2020

Topline data from pivotal phase II/III VALO study of Qtorin rapamycin in pachyonychia congenita

Dec. 24, 2020

FDA approves Klisyri for actinic keratosis on the face or scalp

Dec. 15, 2020

First patient dosed in phase II BLUEPRINT study of BLU-5937

Dec. 15, 2020

Popular Stories

University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers
BioWorld Science
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...